Kreocox 90 Tablet contains Etoricoxib 90 mg, a selective cyclooxygenase-2 (COX-2) inhibitor used primarily for the management of pain and inflammation associated with various musculoskeletal and inflammatory conditions. Etoricoxib exerts its therapeutic effect by selectively inhibiting the COX-2 enzyme, thereby reducing the synthesis of prostaglandins responsible for pain and inflammation, while sparing COX-1, which helps maintain gastrointestinal mucosal integrity. Kreocox 90 is indicated for the treatment of osteoarthritis, rheumatoid arthritis, ankylosing spondylitis, and acute gouty arthritis, providing effective relief from joint pain, swelling, and stiffness. It may also be prescribed for the management of chronic musculoskeletal pain and postoperative pain. The recommended dosage and duration of therapy should be individualized based on the patient’s condition and response, with caution advised in patients with cardiovascular risk factors, gastrointestinal disorders, renal or hepatic impairment. Common adverse effects include headache, dizziness, gastrointestinal discomfort, and elevated blood pressure. Kreocox 90 should be used under medical supervision, particularly in patients with a history of cardiovascular disease or those on concomitant anticoagulant therapy. Regular monitoring and adherence to prescribed dosage are essential to minimize potential risks and optimize therapeutic outcomes.